Wall Street brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce earnings of $0.44 per share for the current quarter, Zacks reports. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest EPS estimate is $0.52 and the lowest is $0.31. Supernus Pharmaceuticals reported earnings of $0.49 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 10.2%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $2.37 per share for the current year, with EPS estimates ranging from $2.15 to $2.70. For the next financial year, analysts forecast that the company will post earnings of $2.94 per share, with EPS estimates ranging from $2.55 to $3.15. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.29 by $0.19. The business had revenue of $113.50 million during the quarter, compared to the consensus estimate of $105.36 million. Supernus Pharmaceuticals had a net margin of 27.14% and a return on equity of 27.45%. Supernus Pharmaceuticals’s revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 EPS.
In related news, CFO Gregory S. Patrick sold 20,000 shares of the stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total transaction of $830,600.00. Following the transaction, the chief financial officer now directly owns 67,896 shares of the company’s stock, valued at $2,819,720.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 511.1% in the fourth quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 736 shares in the last quarter. Advisor Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 17.2% in the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 306 shares in the last quarter. Cutler Group LP bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $89,000. Quantbot Technologies LP bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at $113,000. Finally, Gryphon Financial Partners LLC lifted its stake in shares of Supernus Pharmaceuticals by 302.5% in the third quarter. Gryphon Financial Partners LLC now owns 4,037 shares of the specialty pharmaceutical company’s stock valued at $204,000 after buying an additional 3,034 shares in the last quarter. 97.89% of the stock is currently owned by institutional investors and hedge funds.
Shares of SUPN stock traded down $0.76 during midday trading on Friday, hitting $37.74. 21,409 shares of the company were exchanged, compared to its average volume of 630,979. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 18.41 and a beta of 1.62. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.90 and a current ratio of 3.06. Supernus Pharmaceuticals has a 52 week low of $30.05 and a 52 week high of $61.25.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Story: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.